<DOC>
	<DOCNO>NCT01563926</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial evaluate new liquid somatropin formulation child growth hormone deficiency .</brief_summary>
	<brief_title>Evaluating Acceptance New Liquid Somatropin Formulation Children With Growth Hormone Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Written Informed Consent patient and/or guardian/parents Patients one follow diagnosis : Growth failure due growth hormone deficiency ( GHD ) , Turner syndrome , growth retardation child chronic renal disorder Patients willing inject answer questionnaire young patient whose parents/guardian willing inject child answer questionnaires Patients growth hormone therapy least 6 week enter trial Pregnancy breast feed woman Suspected known allergy trial product Other daily injection therapy ( nongrowth hormone , e.g insulintherapy ) Participating trial involve investigational product within last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>